What is the most common cellular type of rectosigmoid malignancy and its percentage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Common Cellular Type of Rectosigmoid Malignancy and Its Percentage

The most common cellular type of rectosigmoid malignancy is adenocarcinoma, accounting for approximately 95-98% of all rectosigmoid cancers. 1

Histological Classification of Rectosigmoid Malignancies

Adenocarcinomas represent the overwhelming majority of rectosigmoid cancers, with several subtypes recognized:

  1. Conventional adenocarcinoma (NOS - not otherwise specified) - This is the most common subtype, typically arising from adenomas 1

  2. Specific adenocarcinoma subtypes:

    • Mucinous adenocarcinoma (11.6% of cases) - Characterized by >50% of tumor comprised of extracellular mucin pools containing malignant glands or individual tumor cells 1, 2
    • Signet-ring cell adenocarcinoma (4.6% of cases) - Characterized by >50% of tumor demonstrating signet-ring cell morphology with intracytoplasmic mucin displacing and indenting nuclei 1, 2
    • Medullary carcinoma - Shows solid sheets of malignant cells with indistinct cell boundaries, vesicular nuclei, prominent nucleoli, and inflammatory infiltrates 1
    • Serrated adenocarcinoma - Demonstrates glandular serrations, often slit-like, with low nuclear to cytoplasmic ratio 1
    • Micropapillary adenocarcinoma - Shows small, rounded clusters of tumor cells within stromal spaces mimicking vascular channels 1
    • Adenoma-like adenocarcinoma - At least 50% of invasive tumor has adenoma-like appearance with villous architecture 1

Molecular and Genetic Characteristics

Most rectosigmoid adenocarcinomas are characterized by:

  • Chromosomal instability pathway (CIN) 1
  • Microsatellite instability (MSI) is rare in rectal cancer (only a few percent) 1
  • Approximately one-third are associated with aberrant DNA methylation 1
  • Common genetic alterations include:
    • APC gene mutations (tumor suppressor)
    • Inactivation of P53 and TGFβ pathways
    • Activation of oncogenes like KRAS and PI3CKA
    • BRAF mutations are rare in rectal cancer 1

Clinical Implications

The histological subtype has significant implications for prognosis and treatment:

  • Signet-ring cell adenocarcinoma is associated with worse stage-for-stage survival compared to conventional adenocarcinoma 1
  • Medullary carcinoma is almost invariably associated with microsatellite instability and generally has a good prognosis 1
  • Micropapillary adenocarcinoma is associated with adverse pathological features including extramural venous invasion and lymph node metastasis 1
  • Adenoma-like adenocarcinoma is associated with a good prognosis 1

Diagnostic Considerations

When evaluating rectosigmoid malignancies, histopathological examination should include:

  • Assessment of surgical margins (proximal, distal, and circumferential)
  • Examination of regional lymph nodes (at least 12 nodes recommended)
  • Evaluation of vascular and nerve invasion
  • Histological grading based on gland formation 1

Understanding the cellular type of rectosigmoid malignancy is crucial for determining prognosis and guiding treatment decisions that will ultimately affect morbidity, mortality, and quality of life outcomes.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.